Advanced molecular diagnostics and personalized Supportive Oligonucleotide Therapy — precision-guided support for cancer care and chronic infections, custom-designed from your unique biological data.
Overview
RGCC testing and SOT(Q-Restrain) therapy represent the frontier of personalized medicine — using your own molecular data to design targeted interventions.
RGCC (Research Genetic Cancer Centre) testing provides advanced laboratory analysis of circulating cells and molecular signals in your blood. These insights reveal personalized molecular targets, drug and compound sensitivity profiles, and trackable biomarkers that allow your care team to customize support rather than relying on one-size-fits-all approaches.
SOT(Q-Restrain) — Supportive Oligonucleotide Therapy — is a highly personalized therapy developed by RGCC. It utilizes short strands of synthetic antisense oligonucleotides engineered to target and bind to specific messenger RNA (mRNA), disrupting the replication of pathogens like herpes and Lyme-related organisms, or interfering with tumor-related signaling pathways.
At OrthoLiving, RGCC identifies your target and SOT(Q-Restrain) is custom-manufactured to act upon that target. This data-driven, personalized approach represents a paradigm shift from generic protocols to precision-guided molecular support.
Our Philosophy
We combine cutting-edge molecular diagnostics with personalized oligonucleotide therapy within an integrative functional medicine framework.
Advanced RGCC blood analysis identifies personalized molecular targets and drug/compound sensitivity profiles
SOT(Q-Restrain) is custom-manufactured from YOUR RGCC data — no generic, off-the-shelf treatments
Precision-guided approach targeting specific mRNA sequences of pathogens or tumor-related pathways
Clinical data indicates up to 91% success rate for herpes virus elimination over three SOT(Q-Restrain) treatments
Integrative protocol combining SOT(Q-Restrain) with IV nutrition, peptides, and lifestyle optimization for comprehensive support
Your Journey
A structured process designed to deliver personalized, evidence-informed care.
Thorough review of your case, current treatments, and goals to determine if RGCC testing and SOT(Q-Restrain) therapy are appropriate for your situation.
A blood sample is collected and sent to an RGCC-affiliated laboratory. Results typically return within 2–4 weeks with detailed molecular findings and target identification.
If indicated, SOT(Q-Restrain) is custom-manufactured for your identified targets and administered under clinical guidance via IV infusion, followed by post-care instructions.
Periodic re-evaluation with repeat RGCC testing as needed, integrated with supportive therapies including IV nutrition, peptides, and lifestyle adjustments.
Benefits
Evidence-informed approaches designed to support meaningful health improvements. Individual results vary.
SOT(Q-Restrain) is custom-designed from YOUR blood data to target specific molecular sequences — not a generic treatment applied to everyone.
Antisense oligonucleotides bind directly to pathogen mRNA, disrupting replication of specific viruses or organisms at the genetic level.
Clinical data from RGCC indicates three consecutive SOT(Q-Restrain) treatments may achieve a 91% success rate in eliminating herpes virus activity.
By silencing chronic pathogens, SOT(Q-Restrain) may free your immune system to redirect resources toward broader protection and healing.
For cancer support, SOT(Q-Restrain) may interfere with tumor-related signaling pathways based on your RGCC sensitivity profile.
SOT(Q-Restrain) is combined with IV nutrition, peptide protocols, and lifestyle optimization for comprehensive, multi-pathway therapeutic support.
Applications
Designed to support a wide range of health goals and concerns.
The OrthoLiving Difference
We partner directly with RGCC, the global leader in molecular and genetic research, for advanced circulating cell analysis and personalized target identification.
Every SOT(Q-Restrain) treatment is individually manufactured from your personal RGCC data — ensuring true molecular precision, not a generic protocol.
SOT(Q-Restrain) is delivered within our comprehensive functional medicine ecosystem, supported by IV therapies, peptide protocols, and lifestyle optimization.
Our AI-enhanced clinical platform streamlines your care journey from scheduling through follow-up, ensuring seamless coordination at every step.
The Science
Antisense oligonucleotide technology represents one of the most targeted therapeutic approaches in modern molecular medicine. SOT(Q-Restrain) utilizes short synthetic nucleotide sequences designed to bind complementarily to specific messenger RNA (mRNA) targets identified through RGCC analysis. This binding disrupts the translation of pathogen-encoded proteins or tumor-associated signaling molecules, effectively silencing their expression at the genetic level.
For chronic viral infections such as herpes simplex, SOT(Q-Restrain) targets the mRNA sequences essential for viral replication and latency maintenance. Clinical data from RGCC laboratories and real-world clinical experience indicate that three consecutive SOT(Q-Restrain) treatments may achieve a 91% success rate in eliminating herpes virus activity — a fundamentally different approach from suppressive antiviral medications that only manage symptoms.
RGCC's circulating tumor cell (CTC) and cancer stem cell analysis provides molecular sensitivity profiling that informs both SOT(Q-Restrain) design and broader treatment strategy. This data-driven approach allows clinicians to move beyond empirical therapy selection toward precision-guided molecular interventions tailored to each patient's unique biological landscape.
Questions
Schedule your consultation to learn how RGCC testing and SOT(Q-Restrain) therapy may support your path to targeted healing and immune optimization.
Schedule Your ConsultationMedical Disclaimer: The information on this website is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. All care recommendations are made after appropriate consultation with a qualified healthcare professional.